Aliases & Classifications for Mouth Disease

MalaCards integrated aliases for Mouth Disease:

Name: Mouth Disease 12 14
Mouth Diseases 42 69
Abnormality of the Mouth 29
Mouth Disorders 41

Classifications:



External Ids:

Disease Ontology 12 DOID:403
MeSH 42 D009059
NCIt 47 C27641 C3240
UMLS 69 C0026636

Summaries for Mouth Disease

MedlinePlus : 41 your mouth is one of the most important parts of your body. any problem that affects your mouth can make it hard to eat, drink or even smile. some common mouth problems include cold sores - painful sores on the lips and around the mouth, caused by a virus canker sores - painful sores in the mouth, caused by bacteria or viruses thrush - a yeast infection that causes white patches in your mouth leukoplakia - white patches of excess cell growth on the cheeks, gums or tongue, common in smokers dry mouth - a lack of enough saliva, caused by some medicines and certain diseases gum or tooth problems bad breath treatment for mouth disorders varies, depending on the problem. keeping a clean mouth by brushing and flossing often is important.

MalaCards based summary : Mouth Disease, also known as mouth diseases, is related to herpangina and hand, foot and mouth disease, and has symptoms including coughing, halitosis and oral manifestations. An important gene associated with Mouth Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Metronidazole and sodium fluoride have been mentioned in the context of this disorder. Affiliated tissues include kidney, lung and bone, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 A gastrointestinal system disease that is located in the mouth.

Related Diseases for Mouth Disease

Diseases related to Mouth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 220)
id Related Disease Score Top Affiliating Genes
1 herpangina 30.9 HMGB1 IFNG IL10 IL17F IL6 SCARB2
2 hand, foot and mouth disease 12.3
3 hemangioma of spleen 10.9 CRP IFNG IL6
4 collagenopathy type 2 alpha 1 10.9 CRP IL6
5 cyclosporiasis 10.9 IFNG IL10 IL6
6 breast papillary carcinoma 10.9 CRP IL10 IL6
7 hepadnavirus infection 10.9 IFNG IL10 IL6
8 hemophagocytic lymphohistiocytosis 10.9 IFNG IL10 IL6
9 dysphagia 10.9 IFNG IL10 IL6
10 conduct disorder 10.9 IFNG IL10 IL6
11 residual stage corticosteroid-induced glaucoma 10.9 CRP IL10 IL6
12 pneumoconiosis 10.9 CRP IFNG IL6
13 orbital osteomyelitis 10.9 IFNG IL10 IL6
14 eye accommodation disease 10.9 IFNG IL10
15 disease of mental health 10.9 IFNG IL10 IL6
16 abnormal retinal correspondence 10.9 IFNG IL10 IL6
17 extrahepatic bile duct adenocarcinoma 10.8 IFNG IL10 IL6
18 melioidosis 10.8 IFNG IL10 IL6
19 epidermolysis bullosa acquisita 10.8 IFNG IL10 STAT1
20 bursitis 10.8 IL6 JAK1
21 peroneal nerve paralysis 10.8 IL10 IL6 TLR9
22 burning mouth syndrome 10.8
23 dermatitis herpetiformis, familial 10.8 CRP IFNG IL6
24 malignant gastric granular cell tumor 10.8 CRP IL6 TLR9
25 x-linked dominant intellectual disability-epilepsy syndrome 10.8 CRP IL1B IL6
26 myelitis 10.8 IFNG IL10 IL6
27 infancy electroclinical syndrome 10.8 IL10 IL1B IL6
28 burn scar 10.8 IFNG IL10 IL6
29 benign neonatal seizures 10.8 CRP IL1B IL6
30 pulmonary plasma cell granuloma 10.8 CRP CTRL IL1B
31 tularemia 10.8 IFNG IL10 TLR9
32 multiple congenital anomalies mental retardation, growth failure and cleft lip palate 10.8 CRP IFNG IL10 IL6
33 early congenital syphilis 10.8 CRP IL6 TLR9
34 left bundle branch hemiblock 10.8 IFNG IL10 STAT1
35 megaloblastic anemia 10.8 CRP IL10 IL1B
36 tonsil cancer 10.8 IFNG IL10 IL1B
37 cornea cancer 10.8 CRP IFNG IL10 IL6
38 esophagus melanoma 10.8 CRP IFNG IL10 IL6
39 mixed mineral dust pneumoconiosis 10.8 CRP IL10 IL6
40 sternal cleft 10.8 HMGB1 IFNG IL1B
41 senile reticular retinal degeneration 10.8 IFNG IL10 IL1B
42 noma 10.8 IL10 IL1B IL6
43 high pressure neurological syndrome 10.8 IL10 IL1B IL6
44 ethmoid sinus cancer 10.8 IFNG IL1B STAT1
45 bartonellosis 10.8 IFNG IL10 IL1B
46 palmoplantar keratosis 10.8 IL10 IL1B IL6
47 askin's tumor 10.8 IFNG IL10 IL1B
48 vacterl association 10.7 IL10 IL1B IL6
49 macroglobulinemia, waldenstrom 1 10.7 CRP IFNG IL10 IL6
50 pancreas lymphoma 10.7 CRP IL1B IL6

Graphical network of the top 20 diseases related to Mouth Disease:



Diseases related to Mouth Disease

Symptoms & Phenotypes for Mouth Disease

UMLS symptoms related to Mouth Disease:


coughing, halitosis, oral manifestations, snoring, sore throat, vertigo/dizziness, equilibration disorder

MGI Mouse Phenotypes related to Mouth Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.14 CRP FUBP1 IFNG IL10 IL1B IL6
2 hematopoietic system MP:0005397 10.13 FUBP1 IFNG IL10 IL17F IL1B IL6
3 immune system MP:0005387 10.1 SCARB2 STAT1 TLR9 TRPV1 CRP FUBP1
4 digestive/alimentary MP:0005381 9.97 IFNG IL10 IL17F IL6 ITGAV PAX9
5 liver/biliary system MP:0005370 9.7 FUBP1 IFNG IL10 IL6 JAK1 STAT1
6 neoplasm MP:0002006 9.5 IFNG IL10 IL1B IL6 ITGAV STAT1
7 renal/urinary system MP:0005367 9.17 IFNG IL6 ITGAV JAK1 SCARB2 TLR9

Drugs & Therapeutics for Mouth Disease

Drugs for Mouth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1900)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 443-48-1 4173
2 sodium fluoride Approved Phase 4,Phase 3,Phase 1,Phase 2 7681-49-4
3
Triclosan Approved Phase 4,Phase 3,Phase 1,Phase 2 3380-34-5 5564
4
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 564-25-0 54671203
5
Levonorgestrel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 797-63-7, 17489-40-6 13109
6
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 26787-78-0 33613 2171
7
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-43-4 5816
8 Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55-56-1 9552079 2713
10
Hexetidine Approved Phase 4 141-94-6
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
12
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Phase 1 103-90-2 1983
13
Aminocaproic Acid Approved, Investigational Phase 4,Phase 3 60-32-2 564
14
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 137-58-6 3676
15
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
16
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120014-06-4 3152
17
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
18
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19982-08-2 4054
19
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
21
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
22
Docosanol Approved, Investigational Phase 4 30303-65-2, 661-19-8 12620
23
Sucralfate Approved Phase 4,Phase 3,Phase 2 54182-58-0
24
Calcium Carbonate Approved Phase 4,Phase 2,Phase 3,Phase 1 471-34-1
25
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
26
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
27
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-78-2 2244
28
Phenprocoumon Approved Phase 4,Phase 3,Phase 1 435-97-2 9908 54680692
29
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1 55142-85-3 5472
30
Warfarin Approved Phase 4,Phase 2,Phase 3,Phase 1 81-81-2 6691 54678486
31
Insulin Glargine Approved Phase 4,Phase 3 160337-95-1
32
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
33
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
34
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757
35
Norethindrone Approved Phase 4,Phase 3,Phase 2,Phase 1 68-22-4 6230
36
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59729-33-8 2771
37
Clarithromycin Approved Phase 4,Phase 2,Phase 3,Phase 1 81103-11-9 84029
38
Clofazimine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 2030-63-9 2794
39
Rifabutin Approved Phase 4,Phase 3,Phase 1 72559-06-9 6323490
40
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 83905-01-5 55185 53477736 447043
41
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 1972-08-3 16078 2978
42
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1 274693-27-5 9871419
43
Ciclopirox Approved, Investigational Phase 4,Phase 1 29342-05-0 2749
44
Isotretinoin Approved Phase 4,Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
45
Salicylic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 69-72-7 338
46
Iloprost Approved, Investigational Phase 4,Phase 3,Phase 2 78919-13-8 6443959
47
Simvastatin Approved Phase 4,Phase 2,Phase 3,Phase 1 79902-63-9 54454
48
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3 427-51-0
49
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1 57-63-6 5991
50
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 85721-33-1 2764

Interventional clinical trials:

(show top 50) (show all 10000)

id Name Status NCT ID Phase Drugs
1 The Treatment of Periodontal Diseases Unknown status NCT01318928 Phase 4 Metronidazol
2 Clinical Investigation of the Effects of Colgate Total Toothpaste as Compared to a Matching Placebo on Periodontal Disease and Systemic Inflammatory Markers Unknown status NCT02670135 Phase 4 Triclosan Containing Toothpaste;Triclosan Free Toothpaste
3 Effect of Actonel on Periodontal Health of Postmenopausal Women Unknown status NCT00594334 Phase 4 Risedronate
4 Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care Unknown status NCT01195493 Phase 4
5 Norplant and Irregular Bleeding/Spotting Unknown status NCT00064766 Phase 4 doxycycline
6 Metronidazole and Amoxicillin for the Treatment of Type 2 Diabetic Subjects With Periodontitis Unknown status NCT02135952 Phase 4 MTZ+AMX
7 Manually Versus Digitally Fabricated Removable Partial Dentures Unknown status NCT01191073 Phase 4
8 Clinical, Microbiological and Biochemical Effects of the Antimicrobial Photodynamic Therapy Unknown status NCT01532674 Phase 4
9 Study of Scaling and Root Planing With PerioWave Versus Scaling and Root Planing Alone in Chronic Periodontitis Unknown status NCT00297531 Phase 4
10 SRP in Combination With PERIOWAVE in Comparison to SRP Alone in Chronic Periodontitis Unknown status NCT00296881 Phase 4
11 Methodology Antiseptic Application, Influence on Oral Biofilm. Unknown status NCT02267239 Phase 4 essential oils, immersion;Chlorhexidine, immersion;essential oils, mouthwash;chlorhexidine, mouthwash
12 Evaluation of a Lateral Window Technique Augmentation for Maxillary Sinus Using Ultrasound Activated Pins Unknown status NCT02449707 Phase 4
13 Randomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants Patients Unknown status NCT02238288 Phase 4 Aminocaproic acid;lidocaine and epinephrine;Paracetamol
14 Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography Unknown status NCT00172965 Phase 4
15 Laser De-epithelialization for Epithelial Exclusion in Root Coverage Procedure: a Clinical Study Unknown status NCT02626117 Phase 4
16 Connective Tissue Graft Versus Mucograft Collagen Matrix for Coverage of Multiple Gingival Recession Defects Unknown status NCT01440426 Phase 4
17 Platelet Rich Fibrin in the Treatment of Palatal Wounds Unknown status NCT02438046 Phase 4
18 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4 Ebixa;donepezil
19 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4 methylorednisolone
20 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
21 Adhesion of Connective Tissue Around Laser-treated Abutments for Dental Implants - Clinical Trial in Humans Unknown status NCT01954485 Phase 4
22 Anticaries Effect of Probiotic Lactobacillus Brevis CD2 (Lb CD2). Unknown status NCT01778699 Phase 4
23 Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
24 Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis) Unknown status NCT00467662 Phase 4 Acyclovir 5%;Docosanol 10%
25 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
26 ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial Unknown status NCT02016807 Phase 4
27 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
28 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
29 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
30 A Trial to Evaluate Efficacy of Heart-protecting Musk Pill Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
31 An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
32 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
33 Periodontal Therapy in Coronary Artery Patients Unknown status NCT01609725 Phase 4
34 Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation Unknown status NCT00776633 Phase 4 aspirin;clopidogrel;oral anticoagulation
35 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
36 Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy Unknown status NCT02264743 Phase 4 Femoston Conti;EVOREL® CONTI
37 Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J) Unknown status NCT00974493 Phase 4 Antibiotics
38 Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD Unknown status NCT01820832 Phase 4 Calcitriol
39 Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
40 Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
41 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4 Rifabutin, Clarithromycin, and Clofazimine
42 The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
43 Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD) Unknown status NCT00965809 Phase 4 Tetrahydrocannabinol
44 Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease Unknown status NCT02514642 Phase 4 low-dose ticagrelor;Clopidogrel
45 Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
46 Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease Unknown status NCT01383083 Phase 4
47 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease Unknown status NCT02010762 Phase 4 Vitamin D;Placebo
48 Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
49 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
50 Protective Effects of Oral L-Arginine CI-AKI Unknown status NCT02455960 Phase 4

Search NIH Clinical Center for Mouth Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: mouth diseases

Genetic Tests for Mouth Disease

Genetic tests related to Mouth Disease:

id Genetic test Affiliating Genes
1 Abnormality of the Mouth 29

Anatomical Context for Mouth Disease

MalaCards organs/tissues related to Mouth Disease:

39
Kidney, Lung, Bone, Breast, Liver, Heart, Prostate

Publications for Mouth Disease

Articles related to Mouth Disease:

(show top 50) (show all 876)
id Title Authors Year
1
Clinical Significance and Prognostic Effect of Serum 25-hydroxyvitamin D Concentrations in Critical and Severe Hand, Foot and Mouth Disease. ( 28489032 )
2017
2
Market Impact of Foot-and-Mouth Disease Control Strategies: A UK Case Study. ( 28920059 )
2017
3
Synonymous codon usage analysis of hand, foot and mouth disease viruses: A comparative study on coxsackievirus A6, A10, A16, and enterovirus 71 from 2008 to 2015. ( 28602802 )
2017
4
Tailoring Diagnostic Studies in Hand, Foot, and Mouth Disease: Utility of PCR testing of Lesional Skin. ( 28940373 )
2017
5
A sudden paediatric death due to hand, foot and mouth disease: the importance of vigilance. ( 28866699 )
2017
6
Spatio-temporal clustering analysis and its determinants of hand, foot and mouth disease in Hunan, China, 2009-2015. ( 28946852 )
2017
7
Severe hand, foot and mouth disease associated with Coxsackievirus A10 infections in Xiamen, China in 2015. ( 28577423 )
2017
8
A Case-control Study on Risk Factors for Severe Hand, Foot and Mouth Disease. ( 28084311 )
2017
9
The exposure-response relationship between temperature and childhood hand, foot and mouth disease: A multicity study from mainland China. ( 28069250 )
2017
10
Antiviral activity of acid beta-glucosidase 1 on enterovirus 71, a causative agent of hand, foot and mouth disease. ( 28141506 )
2017
11
Structures of foot and mouth disease virus pentamers: Insight into capsid dissociation and unexpected pentamer reassociation. ( 28937999 )
2017
12
Vitamin D receptor protects glioblastoma A172A cells against Coxsackievirus A16 infection induced cell death in the pathogenesis of hand, foot, and mouth disease. ( 28943436 )
2017
13
Economic costs and health-related quality of life for hand, foot and mouth disease (HFMD) patients in China. ( 28934232 )
2017
14
Epidemiological and genetic analysis concerning the non-enterovirus 71 and non-coxsackievirus A16 causative agents related to hand, foot and mouth disease in Anyang city, Henan Province, China, from 2011 to 2015. ( 28480969 )
2017
15
Derivation and Validation of a Mortality Risk Score for Severe Hand, Foot and Mouth Disease in China. ( 28611398 )
2017
16
Development of a Feature and Template-Assisted Assembler and Application to the Analysis of a Foot-and-Mouth Disease Virus Genotyping Microarray. ( 28045937 )
2017
17
Clinical significance of inflammatory cytokine and chemokine expression in hand, foot and mouth disease. ( 28447721 )
2017
18
A mild phenotype of hand, foot and mouth disease caused by Coxsackievirus A6. ( 28681725 )
2017
19
Dendrimeric peptides can confer protection against foot-and-mouth disease virus in cattle. ( 28949998 )
2017
20
Morphological characteristics of fatal pediatric hand, foot and mouth disease: A clinicopathological study with related receptors of EV71. ( 28756983 )
2017
21
Molecular characterization of circulating Foot and mouth disease virus (FMDV) serotype O topotype EA-3 and serotype A (African topotype) genotype IV in Egypt, 2016. ( 28888656 )
2017
22
Clinical features for 89 deaths of hand, foot and mouth disease in Guangxi, China, 2014. ( 28882666 )
2017
23
The impact of hand, foot and mouth disease control policies in Singapore: A qualitative analysis of public perceptions. ( 28533530 )
2017
24
Single-cell analysis reveals the relevance of foot-and-mouth disease virus persistence to emopamil-binding protein gene expression in host cells. ( 28916923 )
2017
25
Molecular vaccine prepared by fusion of XCL1 to the multi-epitope protein of foot-and-mouth disease virus enhances the specific humoural immune response in cattle. ( 28929328 )
2017
26
An economic assessment of foot and mouth disease in Japan. ( 28926015 )
2017
27
Monitoring hand, foot and mouth disease by combining search engine query data and meteorological factors. ( 28898935 )
2017
28
Concurrent vaccination of goats with foot and mouth disease (FMD) and peste des petits ruminants (PPR) booster vaccines. ( 28940134 )
2017
29
Temporal and spatial analysis of hand, foot, and mouth disease in relation to climate factors: A study in the Mekong Delta region, Vietnam. ( 28063653 )
2017
30
Alteration of serum high-mobility group protein 1 (HMGB1) levels in children with enterovirus 71-induced hand, foot, and mouth disease. ( 28445307 )
2017
31
Genetic characterization of enterovirus strains identified in Hand, Foot and Mouth Disease (HFMD): Emergence of B1c, C1 subgenotypes, E2 sublineage of CVA16, EV71 and CVA6 strains in India. ( 28577914 )
2017
32
Correction for Nelson et al., "Predicting the Ability of Preclinical Diagnosis To Improve Control of Farm-to-Farm Foot-and-Mouth Disease Transmission in Cattle". ( 28947511 )
2017
33
Hand, foot, and mouth disease in mainland China before it was listed as category C disease in May, 2008. ( 28948918 )
2017
34
Working towards consensus: the need for coordinated policies to assist control of foot and mouth disease and emerging disease threats in South-East Asia. ( 28926033 )
2017
35
Determination of optimal age for single vaccination of growing pigs with foot-and-mouth disease bivalent vaccine in South Korea. ( 28943596 )
2017
36
Atypical hand, foot and mouth disease due to Coxsackievirus A6 in a traveler returning from Indonesia to Italy. ( 28498983 )
2017
37
Hand, foot and mouth disease in adult patients. ( 28776773 )
2017
38
Proximal onycholysis as a complication of hand, foot, and mouth disease. ( 28083877 )
2017
39
Spatial Clustering of Severe Hand-Foot-Mouth Disease Cases in Hainan Island, China. ( 28890503 )
2017
40
Epidemiology of 45,616 suspect cases of Hand, Foot and Mouth Disease in Chongqing, China, 2011-2015. ( 28422128 )
2017
41
Therapeutic efficacy of phentolamine in the management of severe hand, foot and mouth disease combined with pulmonary edema. ( 28413485 )
2017
42
eEF1G interaction with foot-and-mouth disease virus nonstructural protein 2B: Identification by yeast two-hybrid system. ( 28942178 )
2017
43
Spatiotemporal risk mapping of hand, foot and mouth disease and its association with meteorological variables in children under 5 years. ( 28891456 )
2017
44
The foot-and-mouth disease carrier state divergence in cattle. ( 27147736 )
2016
45
Foot-and-Mouth Disease in a Small Sample of Experimentally Infected Pronghorn (Antilocapra americana). ( 27525593 )
2016
46
Cyclical Patterns of Hand, Foot and Mouth Disease Caused by Enterovirus A71 in Malaysia. ( 27010319 )
2016
47
Transmission of Hand, Foot and Mouth Disease and Its Potential Driving Factors in Hong Kong. ( 27271966 )
2016
48
Changes of circulating Th22 cells in children with hand, foot, and mouth disease caused by enterovirus 71 infection. ( 28030850 )
2016
49
Short-term effects of meteorological factors on hand, foot and mouth disease among children in Shenzhen, China: Non-linearity, threshold and interaction. ( 26386448 )
2016
50
Cost-benefit analysis of foot and mouth disease control in Ethiopia. ( 27664449 )
2016

Variations for Mouth Disease

Expression for Mouth Disease

Search GEO for disease gene expression data for Mouth Disease.

Pathways for Mouth Disease

Pathways related to Mouth Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 CRP EIF4G1 HMGB1 IFNA1 IFNG IL10
2
Show member pathways
13.57 EIF4G1 IFNA1 IFNG IL10 IL1B IL6
3
Show member pathways
13.39 EIF4G1 IFNA1 IFNG IL10 IL17F IL1B
4
Show member pathways
13.01 IFNA1 IL1B IL6 JAK1 STAT1 TLR9
5
Show member pathways
12.93 IFNA1 IFNG IL10 IL1B IL6 STAT1
6
Show member pathways
12.9 EIF4G1 IFNA1 IFNG IL10 IL1B IL6
7
Show member pathways
12.75 HMGB1 IFNA1 IFNG IL1B IL6
8
Show member pathways
12.75 IFNA1 IFNG IL1B IL6 JAK1 MX1
9 12.72 IFNA1 IL6 ITGAV JAK1 MX1 STAT1
10
Show member pathways
12.63 IFNG IL10 IL17F IL1B IL6 JAK1
11
Show member pathways
12.61 IFNG IL10 IL17F IL1B IL6 JAK1
12
Show member pathways
12.59 EIF4G1 IFNA1 IFNG JAK1 MX1 STAT1
13 12.55 IFNA1 IFNG IL10 IL1B JAK1 STAT1
14
Show member pathways
12.39 IFNG IL17F IL1B IL6 JAK1
15
Show member pathways
12.36 IFNA1 IFNG IL6 JAK1 STAT1
16
Show member pathways
12.33 IFNG IL1B IL6 JAK1 STAT1
17
Show member pathways
12.31 IFNG IL10 IL1B JAK1 STAT1
18 12.24 IFNG IL6 JAK1 STAT1 TLR9
19
Show member pathways
12.24 IFNA1 IFNG IL10 IL6 JAK1 STAT1
20
Show member pathways
12.17 IFNG IL1B IL6 JAK1 STAT1 TLR9
21 12.09 IFNG